Fabrikant-profiel
Allegiant Health
Farmaceutisch bedrijf10 producten gevolgd
10
producten gevolgd
1.077.536
totaal meldingen
127
recalls geregistreerd
58,2%
ernstig algeheel
Producten
10 van 10 getoond
| Product | Goedgekeurd | Meldingen ↓ | Top signaal | Recalls |
|---|---|---|---|---|
| — | 500.597 | GI bloeding | 0 | |
kit — | 1974 | 360.069 | — | 100 |
| — | 195.216 | Infectie van de lagere luchtwegen | 1 | |
| — | 14.106 | chronische nierziekte | 0 | |
| 1996 | 5.686 | Rebound maagzuurproductie | 2 | |
| — | 728 | Loopneus | 5 | |
| — | 412 | seizoensgebonden allergie | 1 | |
| — | 347 | Terugkeer van de ziekte | 9 | |
| — | 301 | Toegediend product dat verlopen is | 9 | |
| — | 74 | ziekenhuisopname | 0 |
Recall-geschiedenis · 50 geregistreerd
| Datum | Klasse | Reden | Bedrijf |
|---|---|---|---|
| 17 mrt 2026 | II | Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. | Teva Pharmaceuticals USA, Inc |
| 17 mrt 2026 | II | Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. | Teva Pharmaceuticals USA, Inc |
| 22 nov 2024 | II | Failed Stability Specifications | Jubilant Draximage Inc., dba Jubilant Radiopharma |
| 31 mei 2024 | III | Labeling: Label Mix-up: Some bottles of Ferrum Phosphoricum 200C were incorrectly labeled as Ferrum Metallicum 200C. | Washington Homeopathic Products, Inc. |
| 2 aug 2023 | II | CGMP Deviations | Parker Laboratories, Inc. |
| 26 apr 2023 | II | CGMP Deviations: Firm went out of business and could no longer continue stability studies. | Akorn, Inc. |
| 23 dec 2022 | I | Microbial Contamination of Non-Sterile Products: FDA Laboratory results found product to be contaminated with Bacillus lichenformis and Bacillus sonorensis. | GFA Production Xiamen Co. Ltd. |
| 23 dec 2022 | I | Microbial Contamination of Non-Sterile Products: FDA Laboratory results found product to be contaminated with Bacillus lichenformis and Bacillus sonorensis. | GFA Production Xiamen Co. Ltd. |
| 23 dec 2022 | I | Microbial Contamination of Non-Sterile Products: FDA Laboratory results found product to be contaminated with Bacillus lichenformis and Bacillus sonorensis. | GFA Production Xiamen Co. Ltd. |
| 23 jun 2022 | II | CGMP Deviations: product held outside appropriate storage temperature conditions. | Family Dollar Stores, Llc. |
| 23 jun 2022 | II | CGMP Deviations: product held outside appropriate storage temperature conditions. | Family Dollar Stores, Llc. |
| 23 jun 2022 | II | CGMP Deviations: product held outside appropriate storage temperature conditions. | Family Dollar Stores, Llc. |
| 16 jun 2022 | II | Lack of Assurance of Sterility: Out-of-specification test results obtained for Endotoxin testing. | Jubilant Draximage Inc |
| 13 apr 2022 | II | cGMP deviations: Temperature abuse | Mckesson Medical-Surgical Inc. Corporate Office |
| 18 mrt 2022 | III | Subpotent Drug: low out-of-specification results for Vial 1 assay obtained during stability studies. | Advanced Accelerator Applications USA, Inc. |
| 3 dec 2021 | III | Subpotent Drug: Product contains less Sodium Fluoride than listed on product label. | Dental Alliance Holdings LLC |
| 3 dec 2021 | III | Subpotent Drug: Product contains less Sodium Fluoride than listed on product label. | Dental Alliance Holdings LLC |
| 3 dec 2021 | III | Subpotent Drug: Product contains less Sodium Fluoride than listed on product label. | Dental Alliance Holdings LLC |
| 3 dec 2021 | III | Subpotent Drug: Product contains less Sodium Fluoride than listed on product label. | Dental Alliance Holdings LLC |
| 24 aug 2021 | I | Product Mix-up: Incorrect diluent component included in the kit. | Azurity Pharmaceuticals, Inc. |
| 22 mrt 2021 | II | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | Novo Nordisk Inc |
| 22 mrt 2021 | II | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | Novo Nordisk Inc |
| 22 mrt 2021 | II | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. | Novo Nordisk Inc |
| 21 apr 2020 | II | Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins | Sandoz, Inc |
| 19 mrt 2020 | II | Failed Stability Specifications | Jubilant Draximage Inc |
| 31 okt 2019 | II | Microbial contamination of non-sterile product. | Fagron, Inc |
| 26 sep 2019 | II | Labeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration needles. The product vial is not impacted. | Alkermes, Inc. |
| 28 mei 2019 | II | Lack of Processing Controls. | Synthetopes Inc |
| 28 mei 2019 | II | Lack of Processing Controls. | Synthetopes Inc |
| 25 mrt 2019 | II | Labeling: Incorrect or Missing Lot and/or Exp Date - the label contains an incorrect Exp Date. | Lohxa LLC |
| 11 dec 2018 | I | Labeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating stoppers do not contain latex. The stoppers contain natural rubber latex | Asclemed USA Inc. dba Enovachem |
| 16 nov 2018 | II | cGMP violations noted during the firm's most recent inspection. | CAO Group, Inc. |
| 2 nov 2018 | II | Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg. | Bound Tree Medical, LLC |
| 2 nov 2018 | II | Labeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the Safety Lok Syringe in Model 8600-01120) recommend a midpoint dosage of epinephrine for children between 0 lbs. and 66 lbs. of 0.15mL that has not been approved by FDA for children. Reliance on the current IFU and/or use of the Epi-Safe Syringe as instructed may result in the administration of an inappropriate dosage of epinephrine to young children experiencing anaphylaxis, especially those under 33 lbs. Additionally the Epi Safe syringe does not have the correct markings to allow a health care provider to draw up the correct dosage for children under 33 kg. | Bound Tree Medical, LLC |
| 1 nov 2018 | II | Labeling: Incorrect or Missing Lot and/or Exp date: vials of epinephrine within kit 8600-01100 expired on December 2018, but the outer kit label has an expiration date of January 2020. In addition, device component (syringe) may lack 510(k) clearance. | Bound Tree Medical, LLC |
| 10 sep 2018 | II | Lack of Assurance of Sterility | Pharm D Solutions, LLC |
| 20 jul 2018 | I | Microbial contamination | King Bio Inc. |
| 20 jul 2018 | I | Microbial contamination | King Bio Inc. |
| 20 jul 2018 | I | Microbial contamination | King Bio Inc. |
| 6 jun 2018 | II | Lack of assurance of sterility: Technetium TC-99M Medronate Kit has a reported breach of sterility. | Pharmalucence, Inc. |
| 26 apr 2018 | II | Lack of Assurance of Sterility | Coast Quality Pharmacy LLC |
| 10 apr 2018 | II | Failed Stability Specifications | Pharmalucence, Inc. |
| 3 apr 2018 | II | Lack of Processing Controls. | Kroger Specialty Pharmacy, Inc. |
| 3 apr 2018 | II | Lack of Processing Controls. | Kroger Specialty Pharmacy, Inc. |
| 21 sep 2017 | II | Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%. | Medline Industries Inc |
| 21 sep 2017 | II | Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%. | Medline Industries Inc |
| 21 sep 2017 | II | Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%. | Medline Industries Inc |
| 21 sep 2017 | II | Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%. | Medline Industries Inc |
| 21 sep 2017 | II | Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%. | Medline Industries Inc |
| 21 sep 2017 | II | Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%. | Medline Industries Inc |
Class I = redelijke kans op ernstige schade · Class II = tijdelijk of omkeerbaar · Class III = onwaarschijnlijk schadelijk.
Registratiestatus
Sommige producten van Allegiant Health zijn niet FDA-geregistreerd voor humaan gebruik. Voor ongeregistreerde stoffen (peptiden, SARMs zonder humane registratie) bestaat geen legitieme leverancier voor humaan gebruik. Het ontbreken van een inkooproute is de veiligheidsinformatie.